

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF ART UNIT: 1614  
BRINKMANN, VOLKER ET AL. EXAMINER: MARSCHEL, ARDIN H  
INTERNATIONAL APPLICATION NO: PCT/EP2004/014436  
FILED: DECEMBER 17, 2004  
U.S. APPLICATION NO: 10/583106  
35 USC §371 DATE: JULY 19, 2006  
FOR: USE OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR  
AGONISTS FOR THE TREATMENT OF BRAIN DEGENERATIVE  
DISEASES

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☒ supplemental to the Information Disclosure Statement filed June 18, 2009.
- ☒ before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

- ☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-9273

  
Cozette McAvoy  
Attorney for Applicant  
Reg. No. 60,457

Date: *3rd November 2009*